What Researchers Did
This was a narrative review summarizing treatment options for radiation-induced hemorrhagic cystitis in gynecological cancer survivors, covering HBOT alongside other strategies including bladder irrigation, fulguration, and intravesical agents.
What They Found
HBOT was listed as one of the most established treatment options for radiation cystitis. The review noted that most treatments provide only short-term benefit or carry procedural risks, and that no therapy currently reverses the underlying radiation damage. Novel strategies under development include botulinum toxin and liposomal tacrolimus.
What This Means for Canadian Patients
Radiation cystitis is an OHIP-covered indication for HBOT in Ontario. Many Canadian women who survive cervical, uterine, or ovarian cancer develop late bladder complications from pelvic radiation. This review reinforces that HBOT is among the most evidence-based treatments available for radiation-related bladder bleeding.
Canadian Relevance
Radiation cystitis is an OHIP-covered indication for HBOT in Ontario.
Study Limitations
This is a narrative review without systematic analysis or meta-analysis; the evidence levels for specific treatments vary and the paper does not critically assess the methodological quality of included studies.